EquiVita Genetics
The computed 12-month bankruptcy probability of EquiVita Genetics is 2.2% (moderate). The 2024 annual accounts show negative equity (€-40k) and a net result of €-137k. Equity is shrinking by ~150.2% per year across the filed fiscal years. Its solvency ranks better than 10% of 174 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-40k |
| Net result | €-137k |
| Better than sector | 10% |
| Active | 5 yrs |
Mixed profile: strong on profitability, weaker on health.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -103.9% | 55.0% | |
| Net result | €-137k | €16k | |
| Equity | €-40k | €70k | |
| Gross operating margin | €-61k | €41k | |
| Staff costs | €56k | €58k |
Show 11 other metrics
| Fiscal year | 2024 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | €-117k |
| Net profit | €-137k |
| Cash flow | €-117k |
| Staff costs | €56k |
| Income taxes | €300 |
| Dividends | - |
| Total assets | €38k |
| Equity | €-40k |
| Debt | €78k |
| of which ≤ 1y | €18k |
| of which > 1y | €60k |
| Working capital | €-5k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 0.71 |
| Quick ratio | 0.71 |
| Working capital ratio | -13.6% |
| Solvency | -103.9% |
| Debt / equity | -1.96 |
| Long-term debt ratio | -1.51 |
| Interest coverage | -411.31 |
| Gross margin | - |
| Net margin | - |
| ROA | -359.0% |
| ROE | 345.6% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (22 line items)
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €38k |
| Fixed assets | 21/28 | €25k |
| Tangible fixed assets | 22/27 | €25k |
| Current assets | 29/58 | €13k |
| Amounts receivable within one year | 40/41 | €2k |
| Cash & bank | 54/58 | €11k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €38k |
| Equity | 10/15 | €-40k |
| Contributions / capital | 10/11 | €256k |
| Accumulated profits (losses) | 14 | €-296k |
| Amounts payable | 17/49 | €78k |
| Amounts payable after one year | 17 | €60k |
| Amounts payable within one year | 42/48 | €18k |
| Trade debts payable within one year | 44 | €7k |
| Income statement | ||
| Gross operating margin | 9900 | €-61k |
| Operating result | 9901 | €-137k |
| Financial income | 75 | €10 |
| Financial charges | 65 | €284 |
| Result before taxes | 9903 | €-137k |
| Income taxes | 67/77 | €300 |
| Net result for the period | 9904 | €-137k |
| Result to be appropriated | 9905 | €-137k |
| NACE primary | Speur- en ontwikkelingswerk op biotechnologisch gebied(72101) |
| Legal form | Private limited company(610) |
| Incorporation | 09-08-2021 |
| Status | Active |
| Postal code | 3720 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 73040D0330/00C000 | Flanders | 5,092 m² | 1 · 1,258 m² | 19.5 m |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
06-01-2023 Capital increase of €250,000 to €250,000
- €0 → €250.000
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 250000.0,
"delta_eur": 250000.0,
"before_eur": 0.0,
"subscribers": [
{
"kbo": "0811.431.031",
"rrn": null,
"kind": "org",
"name": "CUR@DOMUM",
"share_class": null,
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 310,
"contribution_amount_eur": 250000.0
}
],
"_arith_derived": "before",
"share_emission": {
"agio_eur": null,
"share_form": "nominal",
"share_class": null,
"n_new_shares": 310,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 806.45
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 250000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Jan Lambrecht",
"firm_city": null,
"firm_name": null,
"office_city": "Lummen",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2023-01-06",
"filing_date": "2023-01-04",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2022-12-23",
"unanimous": true,
"under_authorized_capital": true,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0772.385.165",
"name_full": "EquiVita Genetics",
"legal_form": "B.V.",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"plan financier",
"bankattest",
"verslag bedrijfsrevisor"
],
"shareholders_after": [
{
"kbo": "0811.431.031",
"pct": null,
"kind": "org",
"name": "CUR@DOMUM",
"role": null,
"n_shares": 310,
"share_class": null
}
],
"share_classes_after": []
}| Legal nameNL | EquiVita Genetics |